FVC (% predicted) Change from baseline · children over 12 and adults with CFRD
Summary of findings: repaglinide showed no clear difference in FVC % predicted change from baseline compared with insulin (moderate certainty).
1 finding from 1 review
Change in BMI · children over 12 and adults with CFRD
Summary of findings: repaglinide showed no clear difference in BMI (kg/m²) change from baseline compared with insulin (low certainty).
1 finding from 1 review
Hypoglycemia: number of episodes · children over 12 and adults with CFRD
Summary of findings: repaglinide showed no clear difference in hypoglycemia number of episodes compared with insulin (low certainty).
1 finding from 1 review
Transplant or graft survival · pre‐existing and new‐onset diabetes in kidney transplant recipients
It is very uncertain whether more intensive changes transplant or graft survival compared with less intensive insulin therapy (very low certainty).
1 finding from 1 review
Transplant or graft survival · pre‐existing and new‐onset diabetes in kidney transplant recipients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Delayed graft function · pre‐existing and new‐onset diabetes in kidney transplant recipients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
HbA1c (%) · pre‐existing and new‐onset diabetes in kidney transplant recipients
1 finding from 1 review
Delayed graft function · pre‐existing and new‐onset diabetes in kidney transplant recipients
It is very uncertain whether more intensive changes delayed graft function Time frame: 1 to 3 years compared with less intensive insulin therapy (very low certainty).
1 finding from 1 review
FBG (mmol/L) · pre‐existing and new‐onset diabetes in kidney transplant recipients
1 finding from 1 review
Kidney function markers · pre‐existing and new‐onset diabetes in kidney transplant recipients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Death (any cause) · pre‐existing and new‐onset diabetes in kidney transplant recipients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Hypoglycaemia · pre‐existing and new‐onset diabetes in kidney transplant recipients
1 finding from 1 review
Discontinuation of medication due to adverse events · pre‐existing and new‐onset diabetes in kidney transplant recipients
1 finding from 1 review
HbA1c (%) · pre‐existing and new‐onset diabetes in kidney transplant recipients
1 finding from 1 review
FBG (mmol/L) · pre‐existing and new‐onset diabetes in kidney transplant recipients
1 finding from 1 review
Kidney function markers · pre‐existing and new‐onset diabetes in kidney transplant recipients
1 finding from 1 review
Death: unknown time frame · pre‐existing and new‐onset diabetes in kidney transplant recipients
It is very uncertain whether more intensive changes death (any cause) Time frame: 1 to 5 years compared with less intensive insulin therapy (very low certainty).
1 finding from 1 review
Hypoglycaemia · pre‐existing and new‐onset diabetes in kidney transplant recipients
1 finding from 1 review
Discontinuation of medication due to adverse events · pre‐existing and new‐onset diabetes in kidney transplant recipients
1 finding from 1 review
All‐cause mortality
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found